论文部分内容阅读
[目的]观察口服氟伐他汀对临床不稳定型心绞痛(UAP)患者血清IL-18水平的影响,并探讨其临床意义。[方法]选取临床UAP病人67例,随机分为对照组(35例)和氟伐他汀组(32例)。两组患者均给予UAP的常规治疗药物治疗2周;氟伐他汀组在常规治疗的基础上加用氟伐他汀40mg,每晚睡前1次口服。所有研究对象均测定治疗前后的血压(BP)、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高敏C-反应蛋白(hs-CRP)和IL-18水平。[结果]①治疗前后对照组患者的TG、TC及LDL-C浓度无明显变化,而hs-CRP和IL-18水平却有所下降(P﹤0.05)。②治疗2周后,氟伐他汀组患者的TG无明显变化,但是TC、LDL-C、hs-CRP和IL-18水平均较治疗前明显下降(P﹤0.05);与对照组比较,hs-CRP和IL-18的下降幅度更为显著(P﹤0.05)。[结论]氟伐他汀在改善UAP患者血脂浓度的同时,还进一步降低hs-CRP和IL-18浓度,减轻UAP的炎症反应。
[Objective] To observe the effect of oral fluvastatin on the level of serum IL-18 in patients with unstable angina pectoris (UAP) and to explore its clinical significance. [Methods] Sixty - seven clinical UAP patients were randomly divided into control group (35 cases) and fluvastatin group (32 cases). Two groups of patients were given routine treatment of UAP for 2 weeks; fluvastatin group on the basis of routine treatment plus fluvastatin 40mg, 1 night before bedtime oral. All subjects were measured before and after treatment of blood pressure (BP), triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high sensitivity C-reactive protein (hs-CRP) and IL- 18 levels. [Results] ① The levels of TG, TC and LDL-C in the control group before and after treatment showed no significant changes, but the levels of hs-CRP and IL-18 decreased (P <0.05). ② After 2 weeks of treatment, the TG of fluvastatin group did not change significantly, but the levels of TC, LDL-C, hs-CRP and IL-18 were significantly lower than those before treatment (P <0.05); compared with the control group, hs -CRP and IL-18 decreased more significantly (P <0.05). [Conclusion] Fluvastatin can further decrease the concentration of hs-CRP and IL-18 and relieve the inflammatory reaction of UAP, while improving the blood lipid concentration in patients with UAP.